These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17493037)

  • 1. Modulation of experimental autoimmune encephalomyelitis by VLA-2 blockade.
    Tsunoda I; Terry EJ; Marble BJ; Lazarides E; Woods C; Fujinami RS
    Brain Pathol; 2007 Jan; 17(1):45-55. PubMed ID: 17493037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.
    Theien BE; Vanderlugt CL; Eagar TN; Nickerson-Nutter C; Nazareno R; Kuchroo VK; Miller SD
    J Clin Invest; 2001 Apr; 107(8):995-1006. PubMed ID: 11306603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE.
    Theien BE; Vanderlugt CL; Nickerson-Nutter C; Cornebise M; Scott DM; Perper SJ; Whalley ET; Miller SD
    Blood; 2003 Dec; 102(13):4464-71. PubMed ID: 12933585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis.
    Matejuk A; Bakke AC; Hopke C; Dwyer J; Vandenbark AA; Offner H
    J Neurosci Res; 2004 Jul; 77(1):119-26. PubMed ID: 15197745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS.
    Lee JH; Halperin-Sheinfeld M; Baatar D; Mughal MR; Tae HJ; Kim JW; Carter A; Lustig A; Snir O; Lavie G; Okun E; Mattson MP; Sredni B; Taub DD
    Neuromolecular Med; 2014 Jun; 16(2):292-307. PubMed ID: 24272426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE.
    Mindur JE; Ito N; Dhib-Jalbut S; Ito K
    PLoS One; 2014; 9(6):e99068. PubMed ID: 24896098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adhesion Molecule Profile and the Effect of Anti-VLA-4 mAb Treatment in Experimental Autoimmune Encephalomyelitis, a Mouse Model of Multiple Sclerosis.
    Pyka-Fościak G; Lis GJ; Litwin JA
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
    Gan Y; Liu R; Wu W; Bomprezzi R; Shi FD
    J Neuroimmunol; 2012 Jun; 247(1-2):9-15. PubMed ID: 22503411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
    Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
    Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications.
    Sheremata WA; Minagar A; Alexander JS; Vollmer T
    CNS Drugs; 2005; 19(11):909-22. PubMed ID: 16268663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus.
    Breuer J; Korpos E; Hannocks MJ; Schneider-Hohendorf T; Song J; Zondler L; Herich S; Flanagan K; Korn T; Zarbock A; Kuhlmann T; Sorokin L; Wiendl H; Schwab N
    J Neuroinflammation; 2018 Aug; 15(1):236. PubMed ID: 30134924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment.
    Deloire MS; Touil T; Brochet B; Dousset V; Caillé JM; Petry KG
    Mult Scler; 2004 Oct; 10(5):540-8. PubMed ID: 15471371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
    Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinant-regulated onset of experimental autoimmune encephalomyelitis: distinct epitopes of myelin proteolipid protein mediate either acute or delayed disease in SJL/J mice.
    Tuohy VK; Thomas DM; Haqqi T; Yu M; Johnson JM
    Autoimmunity; 1995; 21(3):203-14. PubMed ID: 8822278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/VLA-4.
    Selmaj K; Walczak A; Mycko M; Berkowicz T; Kohno T; Raine CS
    Eur J Immunol; 1998 Jun; 28(6):2035-44. PubMed ID: 9645385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin.
    Ji N; Rao N; Guentzel NM; Arulanandam BP; Forsthuber TG
    J Immunol; 2011 Mar; 186(5):2750-6. PubMed ID: 21270409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis.
    Begolka WS; Vanderlugt CL; Rahbe SM; Miller SD
    J Immunol; 1998 Oct; 161(8):4437-46. PubMed ID: 9780223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomechanical changes in the liver tissue induced by a mouse model of multiple sclerosis (EAE) and the effect of anti-VLA-4 mAb treatment.
    Pyka-Fościak G; Zemła J; Lekki J; Wójcik B; Lis GJ; Litwin JA; Lekka M
    Arch Biochem Biophys; 2022 Oct; 728():109356. PubMed ID: 35868535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis.
    Cannella B; Gaupp S; Tilton RG; Raine CS
    J Neurosci Res; 2003 Feb; 71(3):407-16. PubMed ID: 12526029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment.
    Brocke S; Piercy C; Steinman L; Weissman IL; Veromaa T
    Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6896-901. PubMed ID: 10359810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.